(VIANEWS) – Shares of BERGENBIO (Oslo Børs Benchmark Index_GI: BGBIO.OL) fell by a staggering 12.94% to kr0.36 at 11:21 EST on Wednesday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI is falling 0.75% to kr1,218.23, following the last session’s upward trend. This seems, as yet, a somewhat down trend exchanging session today.
About BERGENBIO
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Earnings Per Share
As for profitability, BERGENBIO has a trailing twelve months EPS of kr-0.73.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BERGENBIO’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for BERGENBIO is 2047128 which is 299.83% above its average volume of 512000.
More news about BERGENBIO (BGBIO.OL).
